Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience

被引：0

作者：

Bose, Subhadeep ^{[1
]}

Khaja, Mujtaba Syed ^{[1
]}

Siva, Asha ^{[1
]}

Wilson, Paula ^{[1
]}

Grist, Helen ^{[1
]}

Murukesh, Nishanth ^{[1
]}

机构：

[1] Worcestershire Acute Hosp NHS Trust, Worcester, W Midlands, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

e21091

引用

页数：1

共 50 条

[1] Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
Surovtsova, Irina
Herth, Felix J. F.
Kokh, Daria B.
Morakis, Philipp
PULMONOLOGY, 2025, 31 (01):
[2] PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF METASTATIC NON-SQUAMOUS NSCLC - A NETWORK META-ANALYSIS
Frederickson, A. M.
Arndorfer, S.
Lorenzi, M.
Insinga, R.
Chandwani, S.
Burke, T.
VALUE IN HEALTH, 2018, 21 : S20 - S20
[3] Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer - real-world single-centre data
Patachi, Bogdana
Jensen, Kristian H.
Gothelf, Anita
Bernsdorf, Mogens
Friborg, Jeppe
Kristensen, Claus A.
ACTA ONCOLOGICA, 2025, 64 : 143 - 146
[4] Pembrolizumab With or Without Maintenance Olaparib for Metastatic Squamous NSCLC That Responded to First-Line Pembrolizumab Plus Chemotherapy
Hochmair, Maximilian
Schenker, Michael
Dols, Manuel Cobo
Kim, Tae Min
Ozyilkan, Ozgur
Smagina, Maria
Leonova, Viktoriya
Kato, Terufumi
Fedenko, Alexander
De Angelis, Flavia
Rittmeyer, Achim
Gray, Jhanelle E.
Greystoke, Alastair
Aggarwal, Himani
Huang, Qinlei
Zhao, Bin
Lara-Guerra, Humberto
Nadal, Ernest
JOURNAL OF THORACIC ONCOLOGY, 2025, 20 (02) : 203 - 218
[5] First-Line Pembrolizumab Plus Chemotherapy for Advanced Squamous NSCLC: Real-World Outcomes at U.S. Oncology Practices
Liu, Stephen V.
Rai, Pragya
Wang, Dong
Hu, Xiaohan
Schwarzenberger, Paul Otto
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
[6] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
Rihua Cheng
Zhen Zhou
Qiao Liu
Advances in Therapy, 2023, 40 : 4298 - 4309
[7] The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China
Cheng, Rihua
Zhou, Zhen
Liu, Qiao
ADVANCES IN THERAPY, 2023, 40 (10) : 4298 - 4309
[8] Pembrolizumab plus chemotherapy versus atezolizumab plus chemotherapy plus /-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison
Halmos, Balazs
Burke, Thomas
Kalyvas, Chrysostomos
Vandormael, Kristel
Frederickson, Andrew
Piperdi, Bilal
LUNG CANCER, 2021, 155 : 175 - 182
[9] Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
Leonetti, Alessandro
Perrone, Fabiana
Puntoni, Matteo
Maglietta, Giuseppe
Bordi, Paola
Bria, Emilio
Vita, Emanuele
Gelsomino, Francesco
De Giglio, Andrea
Gelibter, Alain
Siringo, Marco
Mazzoni, Francesca
Caliman, Enrico
Genova, Carlo
Bertolini, Federica
Guaitoli, Giorgia
Passiglia, Francesco
Delcuratolo, Marco Donatello
Montrone, Michele
Cerea, Giulio
Pasello, Giulia
Roca, Elisa
Belluomini, Lorenzo
Cecere, Fabiana Letizia
Guida, Annalisa
Manzo, Anna
Adamo, Vincenzo
Rastelli, Francesca
Bulotta, Alessandra
Citarella, Fabrizio
Toschi, Luca
Zoratto, Federica
Cortinovis, Diego Luigi
Berardi, Rossana
Follador, Alessandro
Carta, Annamaria
Camerini, Andrea
Salerno, Flavio
Silva, Rosa Rita
Baldini, Editta
Cortellini, Alessio
Brighenti, Matteo
Santoni, Matteo
Malorgio, Francesco
Caminiti, Caterina
Tiseo, Marcello
EUROPEAN JOURNAL OF CANCER, 2024, 202
[10] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
Chen, Pingyu
Wang, Xintian
Zhu, Shengwen
Li, Hongchao
Rui, Mingjun
Wang, Yingcheng
Sun, Haikui
Ma, Aixia
FRONTIERS IN PUBLIC HEALTH, 2022, 10

← 1 2 3 4 5 →